Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Key challenges in treating carcinoid and large cell neuroendocrine tumors

Lynnette Fernandez-Cuesta, PhD, International Agency for Research on Cancer (IARC-WHO), Lyon, France, discusses the challenges and complexities involved in studying and treating carcinoid and large cell neuroendocrine tumors, and how researchers are addressing these challenges. Dr Fernandez-Cuesta highlights the limited number of samples available as a major challenge in studying rare challenges, making it less profitable for pharmaceutical companies to develop drugs and challenging to assess treatment benefits. However, efforts are being made, such as creating registries and networks of experts, and increased funding for basic biology and clinical research. In the case of carcinoids, a key limitation is the scarcity of data and financial resources, while for endocrine carcinomas, innovative approaches are needed to understand their progression and identify therapeutic targets. Studying clonal relationships and utilizing tools like supra-carcinomas may offer insights for early intervention and treatment strategies. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.